Pharmacokinetics, Pharmacodynamics of Bococizumab, a monoclonal antibody to PCSK9, After Single Subcutaneous Injection at 3 Sites [NCT 02043301]

ConclusionsSimilar PK profiles and robust LDL‐C reductions were observed following single 150‐mg s.c. injections of bococizumab administered to the abdomen, thigh, or upper arm in untreated subjects with LDL‐C ≥130 mg/dL. Bococizumab was generally well‐tolerated following a single 150‐mg s.c. administration in this subject population.ClinicalTrials. gov identifier: NCT02043301

Source: Cardiovascular Therapeutics - June 21, 2017 Category: Cardiology Authors: Ellen Q. Wang, Anna Plotka, Joanne Salageanu, Catherine Sattler, Carla Yunis Tags: Original Research Article Source Type: research